| Nov 7 |
Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements
|
| Oct 30 |
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain
|
| Sep 9 |
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
|
| Aug 31 |
Biomerica Full Year 2024 Earnings: US$0.35 loss per share (vs US$0.50 loss in FY 2023)
|
| Aug 29 |
Biomerica reports FY results
|
| Aug 29 |
Biomerica Reports Fiscal 2024 Year End Results
|
| Jul 1 |
Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers
|
